CVT 2511
Latest Information Update: 16 Jul 2002
At a glance
- Originator CV Therapeutics
- Class
- Mechanism of Action Partial fatty acid oxidation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Angina pectoris
Most Recent Events
- 13 Sep 2000 New profile
- 13 Sep 2000 Preclinical development for Angina pectoris in USA (Unknown route)